Important Information:

Some site functionality will be unavailable between 01:00 and 09:00 on Sunday 28th of July for scheduled maintenance. We apologise for any inconvenience caused.

nabtrade outage:

Please be advised that there is a global technology incident impacting NAB and other companies which is preventing clients from being able to login to nabtrade and many of our staff from accessing their laptops and answering client calls. Lengthy call wait times have resulted. We apologise for the inconvenience caused.

Learn more

Forgotten your password?

Authorised Person login

NAB Defence

NAB Defence, your protection against fraud.

Learn more about NAB Defence

Csl focused on creating medical breakthroughs

CSL’s Chief Financial Officer David Lamont discusses the company’s latest earnings, its focus on innovation, and also responds to investor concerns about its valuation.

24 August 2018 09:20 AM

read

Following the healthcare company’s FY 18 results, CSL’s Chief Financial Officer David Lamont and nabtrade’s Customer Insights Manager Vishal Teckchandani discuss:

Data insights on how nabtrade customers are investing in CSL,
Why investors should focus on the company's research & development activities,
If CSL has an appetite for a stock split, and
The CSL-112 trial, which is the largest trial undertaken by CSL for individuals who have suffered a heart attack.

Note: The article referred to in the video can be viewed here.